IN2012DN02200A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02200A
IN2012DN02200A IN2200DEN2012A IN2012DN02200A IN 2012DN02200 A IN2012DN02200 A IN 2012DN02200A IN 2200DEN2012 A IN2200DEN2012 A IN 2200DEN2012A IN 2012DN02200 A IN2012DN02200 A IN 2012DN02200A
Authority
IN
India
Prior art keywords
vivo
gcmaf
macrophages
nagalase
contacting
Prior art date
Application number
Other languages
English (en)
Inventor
Charles Knezevich
Robert Silvetz
Original Assignee
Charles Knezevich
Robert Silvetz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charles Knezevich, Robert Silvetz filed Critical Charles Knezevich
Publication of IN2012DN02200A publication Critical patent/IN2012DN02200A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687—Chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN2200DEN2012 2009-08-22 2010-08-23 IN2012DN02200A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23608809P 2009-08-22 2009-08-22
PCT/US2010/046356 WO2011028485A2 (fr) 2009-08-22 2010-08-23 Activation de macrophages tumoricides, bactéricides ou viricides

Publications (1)

Publication Number Publication Date
IN2012DN02200A true IN2012DN02200A (fr) 2015-08-21

Family

ID=43649882

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2200DEN2012 IN2012DN02200A (fr) 2009-08-22 2010-08-23

Country Status (8)

Country Link
US (1) US20110123591A1 (fr)
EP (1) EP2467154A4 (fr)
CN (1) CN102596223A (fr)
AU (1) AU2010289901A1 (fr)
CA (1) CA2771900A1 (fr)
IN (1) IN2012DN02200A (fr)
TW (1) TW201113372A (fr)
WO (1) WO2011028485A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2832487A1 (fr) * 2011-04-07 2012-10-11 Efranat Ltd. Facteur d'activation des macrophages pour des compositions pharmaceutiques
WO2014113641A1 (fr) * 2013-01-18 2014-07-24 Kline Ellis Régime de glycosidase sélective pour la programmation immunitaire et le traitement du cancer
JP7387603B2 (ja) * 2017-11-29 2023-11-28 フィジーン、エルエルシー 活性化のための線維芽細胞と免疫細胞との相互作用及びそれらの使用
EP3990618A4 (fr) * 2019-06-27 2023-08-09 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Macrophages activés par hdac6, compositions et utilisations associées
RU2717218C1 (ru) * 2019-08-07 2020-03-18 Зайцева Инга Николаевна Способ торможения роста подкожного трансплантата экспериментальной глиобластомы человека u-87, перевитого иммунодефицитным мышам nu/j

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410269B1 (en) * 1995-06-07 2002-06-25 Nobuto Yamamoto Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
US20050103712A1 (en) * 2003-11-13 2005-05-19 Voyce Brian D. Methods and devices for treating severe peripheral bacterial infections

Also Published As

Publication number Publication date
CA2771900A1 (fr) 2011-03-10
WO2011028485A2 (fr) 2011-03-10
US20110123591A1 (en) 2011-05-26
CN102596223A (zh) 2012-07-18
EP2467154A4 (fr) 2013-03-27
EP2467154A2 (fr) 2012-06-27
AU2010289901A1 (en) 2012-03-15
TW201113372A (en) 2011-04-16
WO2011028485A3 (fr) 2011-07-14

Similar Documents

Publication Publication Date Title
EP3208615A3 (fr) Utilisations d'inhibiteurs de hsp90 marqués
IN2012DN02200A (fr)
WO2010091049A3 (fr) Diagnostic et traitement du cancer
EP2272453A4 (fr) Système thérapeutique, instrument thérapeutique et procédé de traitement énergétique de tissus vivants
WO2014135987A3 (fr) Optimisation de fréquence dans un traitement par ultrasons
WO2011127211A3 (fr) Procédés, système et appareil pour la détection, le diagnostic et le traitement de troubles du rythme biologique
WO2013040078A3 (fr) Tissus artificiels pour des utilisations en recherche in vitro, puces de ces tissus et procédés de fabrication correspondants
WO2010047923A3 (fr) Procédés et systèmes de traitement du cancer du sein en utilisant le rayonnement d'un faisceau externe
WO2012048241A3 (fr) Procédé et appareil pour la thermothérapie du cancer de la peau
MX2013000986A (es) Sirna dirigido al vegfa y metodos de tratamiento in vivo.
MX2011010511A (es) Regimen de tratamiento que utiliza neratinib para cancer de mama.
ATE485832T1 (de) Glucoseisomerase zur behandlung von fructose- unverträglichkeit
WO2008095164A3 (fr) Rétroaction biologique
CN201939733U (zh) 病原菌消杀器
WO2011098060A3 (fr) Optimisation de thérapie pour cancéreux par test de polythérapies au moyen de tests in vitro
CN202027947U (zh) 病原菌消杀器
RU2010136626A (ru) Способ усиления действия ультразвука при лечении гипертермией опухолевых тканей путем использования нанокластеров кремния
UA37112U (uk) Спосіб індивідуального підбору продуктів харчування для оздоровлення організму людини
Островський Changes in the cells and tissues of living organisms under the influence of shock-wave therapy (literature review)
UA49735U (ru) Способ лечения больных гиперактивным мочевым пузырем с гиперкинетическим детрузором
RU2010105466A (ru) Способ лечения онкологических заболеваний
UA61552U (ru) Способ лечения замедленной консолидации переломов и ложных суставов костей
UA66744U (ru) Способ оценки эффективности лечения больных неалкогольным стеатогепатитом
TR200804036U (tr) Arter tespit ateli.
UA41374U (ru) Способ восстановления кровообращения в артериях бедренно-подколенного сегмента